Our Mission

We want to foster individualized medicine, contributing with innovative analytical systems to be employed in biomedical research, in clinical laboratories and to be used directly at the patient’s side.

Our work is currently following two major directions:

Prof. Carlotta Guiducci

Trained as an electrical engineer with a specialization in electron device physics, Professor Guiducci has been active in the field of miniaturized label-free molecular assays since the beginning of her career. Her early work led to milestones in the field of label-free DNA analytics featuring electrical as well as optical readout. Among her prominent  achievements the demonstration of the quantification of DNA hybridization via changes of electrodes interface capacitance, and the development of the first fully-integrated CMOS chips featuring arrays based on this sensing approach.

Professor Guiducci is a PI at the EPFL since 2009. Her research in microsystems engineering has focused on the integration and on the interfacing issues of lab-on-chip devices. Her most significant achievements include two lab-on-chip/CMOS integration solutions and a novel technology for microfluidic-embedded microsensors that represent unique and highly exploitable technologies. By leveraging multiple collaborations with clinical partners, companies and other IT and engineering teams, the Guiducci lab has succeeded in developing innovative analytical solutions in the field of therapeutic drug monitoring and in the area of single-cell manipulation and characterization on chip.

The lab in the media:

Bioelectronics in the home… The lab of Prof. Carlotta Guiducci:


Nanotera Plenary meeting 2016:


Presentation of the Nanotera ISYPem2 endeavour:


RTS “CQFD” – Une rencontre avec Carlotta Guiducci et Thierry Buclin (Directeur du Département de Pharmacologie du CHUV de Lausanne):


Special announcements:

Fini les grincements de dents!

Aesyra, spin off de l’EPFL, a développé un produit dentaire novateur permettant de contrôler et de réduire activement le bruxisme. L’entreprise annonce la clôture du premier cycle de financement.

Aesyra is: http://aesyra.com

The company relies on research and translational effort funded in the past years by EPFL, local agencies, initiatives, foundations. I think this is a success story worth mentioning on EPFL channels..